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The utility values were from the AusDiab, which used the Short Form (SF-36) Health Survey, and data from other published reports.
Measure of benefit:
Quality-adjusted life-years (QALYs) were the summary benefit measure and they were discounted at an annual rate of 5%.
Cost data:
The economic analysis included the costs of drugs, consultation visits, diagnostic tests, glycaemic control, hypertension control, protein control, dialysis, and transplants. The resource use data came from various published sources, including Australian reports and the UK Prospective Diabetes Study. The unit costs of tests and most other items were based on data from the Medical Benefits Schedule. All costs were in Australian dollars (AUD) and the price year was 2008. A 5% annual discount rate was applied to future costs.
Analysis of uncertainty:
A probabilistic sensitivity analysis was undertaken to assess the uncertainty underlying all the model inputs, simultaneously, using recommended distributions, and cost-effectiveness acceptability curves were generated. The impact of variations in the starting age for screening and screening participation was tested in a deterministic one-way sensitivity analysis.
Results
Compared with usual care, the cost savings were AUD 133 with intensive glycaemic control for diabetic patients and AUD 825 with an ACE inhibitor for diabetic patients. The additional costs were AUD 352 with intensive blood pressure control for hypertensive patients; AUD 1,345 with screening for diabetes and intensive glycaemic control; AUD 57 with screening for hypertension and intensive blood pressure control; and AUD 153 with screening for proteinuria and an ACE inhibitor for all diabetic patients and anyone who tested positive.
The additional QALYs were 0.075 with intensive glycaemic control for diabetic patients; 0.124 with an ACE inhibitor for diabetic patients; 0.136 with intensive blood pressure control for hypertensive patients; 0.097 with screening for diabetes and intensive treatment; 0.116 with screening for hypertension and intensive treatment; and 0.032 with screening for proteinuria and an ACE inhibitor.
Compared with usual care, the first two strategies were dominant, as they were more effective and less expensive. The incremental costs per QALY gained with the other strategies were AUD 2,588 with intensive blood pressure control for hypertensive patients; AUD 13,866 with screening for diabetes and intensive treatment; AUD 491 with screening for hypertension and intensive treatment; and AUD 4,781 with screening for proteinuria and an ACE inhibitor.
At a threshold of AUD 50,000 per QALY, the probability that the intervention was cost-effective was 85% with intensive glycaemic control for diabetic patients; 88% with an ACE inhibitor for diabetic patients; 82% with intensive blood pressure control for hypertensive patients; 57% with screening for diabetes and intensive treatment; 55% with screening for hypertension and intensive treatment; and 50% with screening for proteinuria and an ACE inhibitor.
The probability that it was cost-saving was 47% with intensive glycaemic control for diabetic patients; 54% with an ACE inhibitor for diabetic patients; 44% with intensive blood pressure control for hypertensive patients; 21% with screening for diabetes and intensive treatment; 31% with screening for hypertension and intensive treatment; and 29% with screening for proteinuria and an ACE inhibitor. The deterministic sensitivity analysis showed that the cost-effectiveness for screening improved as the starting age increased.
